GB Sciences, Inc.
GBLX
Get informed when a big investor buys or sells
+ FollowMarket Cap$40.71K
Close$
Share Statistics
| Market cap | $40,707.00 |
|---|---|
| Enterprise Value | $3.09 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 8.34 |
| Outstanding Shares | 407,071,028 |
Return
| Return on Equity | 17.74% |
|---|---|
| Return on Assets | -1104.47% |
| Return on Invested Capital | 15.94% |
Valuation & Multiples
| P/E Ratio | -0.02 |
|---|---|
| PEG | 0.05 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 31.81 |
| Enterprise Value to EBIT | -3.64 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.99 |
| Debt to Equity | -0.52 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About GB Sciences, Inc.
2 employees
CEO: Andrea Small-Howard Operating across North America and Europe, GB Sciences, Inc. is dedicated to the research and development of plant-based pharmaceuticals. The company specializes in crafting cannabinoid-inspired medications and complex therapeutic formul...